Acute Myocardial Infarction in Cancer Patients

March 12, 2025 updated by: Joo Myung Lee, Samsung Medical Center

Risk and Clinical Outcomes of Acute Myocardial Infarction in Patients With Cancer: A Nationwide Study

Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will be conducted using Korean National Health Insurance Service database. Patients who were diagnosed with cancer from 2002 to 2021 will be included in the study. Using the selected patients, current study will analyze the incidence and prognosis of acute myocardial infarction in cancer patients and the prognosis according to the treatment method for acute myocardial infarction will be compared. Primary outcome will be all-cause death. Secondary outcomes will be myocardial infarction, revascularization, hospitalization for heart failure, stroke, and clinically relevant bleeding.

Study Type

Observational

Enrollment (Estimated)

4500000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
      • Gwangju, Korea, Republic of
        • Chonnam National University Hospital, Chonnam National University Medical School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who were diagnosed with cancer from 2002 to 2021 will be considered in the study. Among these patients, those diagnosed with acute myocardial infarction after the diagnosis with cancer will be included in the study.

Description

Inclusion Criteria:

  • Patients diagnosed with cancer between 2002 and 2021
  • Patients who were diagnosed with acute myocardial infarction after cancer diagnosis

Exclusion Criteria:

  • Patients who died during period of cancer diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Revascularized Group
Cancer patients with diagnosis of acute myocardial infarction that was treated with PCI or CABG
Procedure: Revascularization
Performing PCI or CABG
Medical Group
Cancer patients with diagnosis of acute myocardial infarction that was treated with medical treatment only

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause death
Time Frame: 2-years after diagnosis of acute myocardial infarction
All-cause death which was obtained from death certification collected by Statistics Korea at the Ministry of Strategy and Finance of South Korea
2-years after diagnosis of acute myocardial infarction

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myocardial infarction
Time Frame: 2-years after diagnosis of acute myocardial infarction
Myocardial infarction is defined as presence of the diagnostic codes (ICD-10 I21, I22) in the primary position during hospitalization
2-years after diagnosis of acute myocardial infarction
Revascularization
Time Frame: 2-years after diagnosis of acute myocardial infarction
Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
2-years after diagnosis of acute myocardial infarction
Hospitalization for heart failure
Time Frame: 2-years after diagnosis of acute myocardial infarction
Heart failure events requiring hospitalization defined as presence of the diagnostic codes (I110, I130, I132, I255, I420, I425-I429, I43, I50, I971) in the primary position during hospitalization
2-years after diagnosis of acute myocardial infarction
Stroke
Time Frame: 2-years after diagnosis of acute myocardial infarction
Stroke is defined as ischemic stroke (ICD-10 I63, I64) or intracranial hemorrhage (ICD-10 I60-62), combined with the codes of diagnostic brain imaging.
2-years after diagnosis of acute myocardial infarction
Clinically relevant bleeding
Time Frame: 2-years after diagnosis of acute myocardial infarction
Bleeding requiring hospitalization or transfusion
2-years after diagnosis of acute myocardial infarction

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsung Medical Center

Collaborators

Chonnam National University

Investigators

  • Principal Investigator: Joo Myung Lee, MD, MPH, PhD, Samsung Medical Center
  • Principal Investigator: Seung Hun Lee, MD, PhD, Chonnam National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2002

Primary Completion (Actual)

December 31, 2021

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

February 20, 2024

First Submitted That Met QC Criteria

February 20, 2024

First Posted (Actual)

February 28, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 12, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SMC2023-12-027

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This is National Health Insurance Data Analysis. Therefore, sharing the original patient-level data is not possible under regulation by the Korean government.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Revascularization

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe